Skip to product information
1 of 1

ProPepMD

Semaglutide – 3-Month Supply – 503A Compounded

Semaglutide – 3-Month Supply – 503A Compounded

Regular price $176.00 USD
Regular price $220.00 USD Sale price $176.00 USD
Sale Sold out
Strength
Vial size

This product is available after consultation with a specialist.

An in-person consultation with a RELAX specialist is required to discuss this product. Availability depends on clinical suitability and any applicable prescription requirements.

Call us   Make an appointment

1mg 1mg 1mg

A glucagon-like peptide-1 receptor agonist with an albumin-binding fatty acid side chain conferring an extended half-life suitable for weekly administration. Acts on GLP-1 receptors influencing glucose-dependent insulin secretion, glucagon suppression, gastric emptying and central appetite signalling.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 1 mL, dosed in sequence at 1mg, 1mg and 1mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.

1mg 1mg 2mg

A glucagon-like peptide-1 receptor agonist with an albumin-binding fatty acid side chain conferring an extended half-life suitable for weekly administration. Acts on GLP-1 receptors influencing glucose-dependent insulin secretion, glucagon suppression, gastric emptying and central appetite signalling.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 1 mL, dosed in sequence at 1mg, 1mg and 2mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.

2mg 2mg 2mg

A glucagon-like peptide-1 receptor agonist with an albumin-binding fatty acid side chain conferring an extended half-life suitable for weekly administration. Acts on GLP-1 receptors influencing glucose-dependent insulin secretion, glucagon suppression, gastric emptying and central appetite signalling.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 1 mL, dosed in sequence at 2mg, 2mg and 2mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.

2mg 4mg 4mg

A glucagon-like peptide-1 receptor agonist with an albumin-binding fatty acid side chain conferring an extended half-life suitable for weekly administration. Acts on GLP-1 receptors influencing glucose-dependent insulin secretion, glucagon suppression, gastric emptying and central appetite signalling.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 1 mL, dosed in sequence at 2mg, 4mg and 4mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.

4mg 4mg 4mg

A glucagon-like peptide-1 receptor agonist with an albumin-binding fatty acid side chain conferring an extended half-life suitable for weekly administration. Acts on GLP-1 receptors influencing glucose-dependent insulin secretion, glucagon suppression, gastric emptying and central appetite signalling.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 1 mL, dosed in sequence at 4mg, 4mg and 4mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.

4mg 4mg 6mg

A glucagon-like peptide-1 receptor agonist with an albumin-binding fatty acid side chain conferring an extended half-life suitable for weekly administration. Acts on GLP-1 receptors influencing glucose-dependent insulin secretion, glucagon suppression, gastric emptying and central appetite signalling.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 1 mL, dosed in sequence at 4mg, 4mg and 6mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.

Starter: 1mg, 2mg, 4mg/mL

A glucagon-like peptide-1 receptor agonist with an albumin-binding fatty acid side chain conferring an extended half-life suitable for weekly administration. Acts on GLP-1 receptors influencing glucose-dependent insulin secretion, glucagon suppression, gastric emptying and central appetite signalling.
Supplied as an already reconstituted, ready-to-use sterile aqueous solution in a 1 mL vial at Starter: 1mg, 2mg, 4mg/mL. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.

4mg 6mg 6mg

A glucagon-like peptide-1 receptor agonist with an albumin-binding fatty acid side chain conferring an extended half-life suitable for weekly administration. Acts on GLP-1 receptors influencing glucose-dependent insulin secretion, glucagon suppression, gastric emptying and central appetite signalling.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 1 mL, dosed in sequence at 4mg, 6mg and 6mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.

2mg, 4mg, 6mg

A glucagon-like peptide-1 receptor agonist with an albumin-binding fatty acid side chain conferring an extended half-life suitable for weekly administration. Acts on GLP-1 receptors influencing glucose-dependent insulin secretion, glucagon suppression, gastric emptying and central appetite signalling.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 1 mL, dosed in sequence at 2mg, 4mg and 6mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.

6mg, 6mg, 6mg

A glucagon-like peptide-1 receptor agonist with an albumin-binding fatty acid side chain conferring an extended half-life suitable for weekly administration. Acts on GLP-1 receptors influencing glucose-dependent insulin secretion, glucagon suppression, gastric emptying and central appetite signalling.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 1 mL, dosed in sequence at 6mg, 6mg and 6mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.

6mg 6mg 10mg

A glucagon-like peptide-1 receptor agonist with an albumin-binding fatty acid side chain conferring an extended half-life suitable for weekly administration. Acts on GLP-1 receptors influencing glucose-dependent insulin secretion, glucagon suppression, gastric emptying and central appetite signalling.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 1 mL, dosed in sequence at 6mg, 6mg and 10mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.

4mg, 6mg, 10mg

A glucagon-like peptide-1 receptor agonist with an albumin-binding fatty acid side chain conferring an extended half-life suitable for weekly administration. Acts on GLP-1 receptors influencing glucose-dependent insulin secretion, glucagon suppression, gastric emptying and central appetite signalling.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 1 mL, dosed in sequence at 4mg, 6mg and 10mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.

6mg 10mg 10mg

A glucagon-like peptide-1 receptor agonist with an albumin-binding fatty acid side chain conferring an extended half-life suitable for weekly administration. Acts on GLP-1 receptors influencing glucose-dependent insulin secretion, glucagon suppression, gastric emptying and central appetite signalling.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 1 mL, dosed in sequence at 6mg, 10mg and 10mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.

Maintenance: 10mg, 10mg, 10mg

A glucagon-like peptide-1 receptor agonist with an albumin-binding fatty acid side chain conferring an extended half-life suitable for weekly administration. Acts on GLP-1 receptors influencing glucose-dependent insulin secretion, glucagon suppression, gastric emptying and central appetite signalling.
Supplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 1 mL, dosed in sequence at 10mg, 10mg and 10mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.

Vial size listed by supplier 1 mL

Supplier availability · In stock

View full details